Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation plc (NASDAQ:AMRN) announced the retirement of Joseph T. Kennedy as Executive Vice President and General Counsel, with a search underway for his replacement. Kennedy will remain in his role until a successor is found, ensuring a smooth transition. He has served Amarin for a decade, significantly contributing to its evolution from a clinical stage to a commercial entity. The company aims to capitalize on global market opportunities and is focused on advancing cardiovascular disease management.
Amarin Corporation announced that the MHRA has granted Marketing Authorization for VAZKEPA (icosapent ethyl) in Great Britain, targeting cardiovascular risk reduction in high-risk, statin-treated adults with elevated triglycerides. This follows the EU authorization received earlier. The approval is based on substantial evidence from the REDUCE-IT study, which showed a 25% relative risk reduction in major cardiovascular events. The company emphasizes its commitment to expanding access to VAZKEPA across Europe, addressing urgent unmet needs amid rising cardiovascular disease rates.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on April 29, 2021, at 7:30 a.m. ET to discuss its Q1 2021 financial results and provide an operational update. The call follows the early release of the financial results on the same day. Interested parties can listen via the company's website or by calling 888-506-0062 within the U.S. A replay will be available for two weeks. Management will also take questions from participants during the call.
Amarin focuses on innovative solutions for cardiovascular disease management.
Amarin Corporation announced significant findings from the EVAPORATE trial, presented at the ESC Preventive Cardiology 2021. The trial studied the effect of VASCEPA® (icosapent ethyl) on coronary plaque in patients on statin therapy. Results showed a 17% regression in low attenuation plaque volume over 18 months. At 9 months, significant changes in plaque stability were noted, sustained through 18 months. While the study suggests VASCEPA's potential cardiovascular benefits, the small sample size of 80 patients limits the findings. Further research is needed to fully understand these effects.
Amarin Corporation plc (NASDAQ:AMRN) announces the retirement of John F. Thero as President and CEO, effective August 1, 2021. Karim Mikhail, currently Senior VP and Head of Commercial for Europe, will succeed him. Mikhail brings over 20 years of experience from Merck, where he oversaw the launch of numerous pharmaceutical products. Under Thero's leadership, Amarin achieved significant milestones, including the successful launch of VASCEPA and international expansion plans. The transition aims to position Amarin for accelerated global growth, particularly with its upcoming European launch of VAZKEPA.
Amarin Corporation (NASDAQ: AMRN) is preparing for the commercial launch of VAZKEPA (icosapent ethyl) in Germany, slated for Q3 2021, following its recent EC market authorization. The company has hired 150 sales representatives and plans additional educational initiatives to raise awareness of cardiovascular risks among healthcare professionals. Amarin aims to file reimbursement dossiers in 10 European countries soon, with ongoing expansion plans expected to increase staffing to 300 by year-end 2021. The launch strategy incorporates lessons from COVID-19, emphasizing digital outreach.
Amarin Corporation has received EC approval for its drug VAZKEPA (icosapent ethyl) aimed at reducing cardiovascular risk in high-risk, statin-treated patients in Europe. This milestone follows FDA approval in December 2019. The approval is based on data from the REDUCE-IT study, involving over 8,000 patients, showing a 25% relative risk reduction in major adverse cardiovascular events. VAZKEPA will benefit from ten years of market protection in the EU, with potential patent extensions into 2039, positioning Amarin strongly for its European launch.
Amarin Corporation plc (NASDAQ: AMRN) announced that icosapent ethyl has been included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines and the Egyptian Heart Journal’s Practical Guidance for lipid management. This recognition signifies growing global support for icosapent ethyl as a treatment option in reducing cardiovascular risk, increasing the total number of endorsing organizations to 15. The CCS recommends its use for patients with atherosclerotic cardiovascular disease and elevated triglyceride levels, highlighting its clinical benefits validated by the REDUCE-IT study.
Amarin Corporation (NASDAQ:AMRN) presented significant findings from its REDUCE-IT STROKE study at the International Stroke Conference 2021. The study demonstrated a 28% reduction in first strokes and a 32% reduction in total strokes with VASCEPA compared to placebo. Notably, ischemic strokes saw a 36% decrease without increasing the risk of hemorrhagic strokes among statin-treated patients with elevated cardiovascular risk. The study won the Paul Dudley White International Scholar Award, highlighting its impactful results for stroke prevention.
Amarin Corporation (NASDAQ:AMRN) reported record annual revenue of $614.1 million for 2020, up 43% from 2019, with Q4 revenue at $167.3 million, a 17% increase year-over-year. This growth was driven by increased use of VASCEPA® (icosapent ethyl) despite COVID-19 challenges. Amarin received a positive CHMP opinion for VAZKEPA® in Europe, expecting formal approval in April 2021. The company ended 2020 with a strong balance sheet, totaling $563.4 million in cash and no debt. Amarin anticipates robust growth in 2021, particularly in the U.S. and international markets.
FAQ
What is the current stock price of Amarin (AMRN)?
What is the market cap of Amarin (AMRN)?
